Article

Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig

2020-02-02

Abstract excerpt

2019-nCoV, which is a novel coronavirus emerged in Wuhan, China, at the end of 2019, has caused at least infected 11,844 as of Feb 1, 2020. However, there is no specific antiviral treatment or vaccine currently. Very recently report had suggested that novel CoV would use the same cell entry receptor, ACE2, as the SARS-CoV. In this report, we generated a novel recombinant protein by connecting the extracellular dom...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 97a43d91-73e5-5b20-b3db-77b831412572
DOI: 10.1101/2020.02.01.929976

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 8 closest

Potent neutralization of 2019 novel coronavirus by recombinant ACE2-IgDOI 10.1101/2020.02.01.929976Read

Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig.Semantic proximity Read

AGTR2, One Possible Novel Key Gene for the Entry of 2019-nCoV into Human CellsSemantic proximity Read

A plausible path to contain the spread of 2019 Novel Coronavirus; a computational analysis prompts to the use of ACE2 receptor blockersSemantic proximity Read

Structural basis for receptor recognition by the novel coronavirus from WuhanSemantic proximity Read

ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concernSemantic proximity Read

Can we Succeed in the Fight Against SARS-CoV-2 with its Emerging New Variants?Semantic proximity Read

Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, ChinaSemantic proximity Read

The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and AntibodiesSemantic proximity Read